KEYNOTE-522 Phase 3 Results – Was Pembrolizumab a Win in Triple-Negative Breast Cancer? Breast 2 Mins Read9 By. Peter Schmid, FRCP, MD, PhD Date. 10/11/2023 KEYNOTE-522 Phase 3 Results – Was Pembrolizumab a Win in Triple-Negative Breast…
